Harrow (HROW) Liabilities and Shareholders Equity (2010 - 2026)

Harrow's (HROW) quarterly Liabilities and Shareholders Equity came in at $419.5 million in Q1 2026, up 15.21% year-on-year from $364.2 million in Q1 2025, and up 5.02% quarter-over-quarter from $399.5 million in Q4 2025.

Harrow (HROW) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends

Harrow's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $419.5 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 15.21% year-over-year to $419.5 million in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 8.21% increase from a year earlier, with the FY2025 full-year figure at $399.5 million, up 2.7% from the prior year.
  • Liabilities and Shareholders Equity climbed to $419.5 million in Q1 2026 per HROW's latest filing, from $399.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $419.5 million in Q1 2026 and bottomed at $97.6 million in Q1 2022.
  • The 5-year median for Liabilities and Shareholders Equity is $306.6 million (2024), against an average of $278.0 million.
  • Across the five-year window, Liabilities and Shareholders Equity dropped 8.32% in 2022 and surged 188.98% in 2023, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $157.4 million in 2022, then soared by 98.35% to $312.2 million in 2023, then rose by 24.6% to $389.0 million in 2024, then increased by 2.7% to $399.5 million in 2025, then increased by 5.02% to $419.5 million in 2026.
  • Per Business Quant, the three latest HROW Liabilities and Shareholders Equity figures stand at $419.5 million (Q1 2026), $399.5 million (Q4 2025), and $363.1 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 43.40 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 40.04 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 15.15 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 98.91 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 6.71 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 69.30 Bn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 36.83 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 4.91 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 13.22 Bn
10 Harrow 1.56 Bn 1.47 Bn 27.05 Mn 419.54 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 419.54 Mn
Dec 31, 2025 399.48 Mn
Sep 30, 2025 363.07 Mn
Jun 30, 2025 345.03 Mn
Mar 31, 2025 364.16 Mn
Dec 31, 2024 388.97 Mn
Sep 30, 2024 351.54 Mn
Jun 30, 2024 306.63 Mn
Mar 31, 2024 295.54 Mn
Dec 31, 2023 312.16 Mn
Sep 30, 2023 286.07 Mn
Jun 30, 2023 223.99 Mn
Mar 31, 2023 217.50 Mn
Dec 31, 2022 157.38 Mn
Sep 30, 2022 98.99 Mn
Jun 30, 2022 98.06 Mn
Mar 31, 2022 97.60 Mn
Dec 31, 2021 98.33 Mn
Sep 30, 2021 102.80 Mn
Jun 30, 2021 106.97 Mn